Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing treatment regimens in hepatitis C.

Jama M Darling1, Michael W Fried

  • 1Division of Gastroenterology and Hepatology, University of North Carolina, CB# 7584, 8014 Burnett Womack Building, Chapel Hill, NC 27599-7584, USA. jdarling@med.unc.edu

Clinics in Liver Disease
|December 14, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progression of MASH to cirrhosis, decompensation, and mortality, and the utility of NITs for detection and risk stratification.

Hepatology communications·2026
Same author

Hepatitis B: Part I. Updates on Screening and Prevention.

American family physician·2026
Same author

Hepatitis B: Part II. Updates on Diagnosis and Therapy.

American family physician·2026
Same author

The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASH.

Alimentary pharmacology & therapeutics·2025
Same author

DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy.

Journal of viral hepatitis·2025
Same author

Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design.

Hepatology (Baltimore, Md.)·2024
Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026
See all related articles

This review explores advanced hepatitis C virus (HCV) treatment strategies beyond current guidelines. It examines predicting treatment response, optimizing duration, and managing non-responders for better patient outcomes.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) infection understanding and treatment have rapidly advanced since 1989.
  • Current HCV treatment guidelines provide a foundation for managing this hepatotropic virus.

Purpose of the Study:

  • To review and discuss advanced strategies for hepatitis C virus (HCV) infection treatment.
  • To explore methods beyond current guidelines for optimizing HCV therapy.

Main Methods:

  • Analysis of pretreatment factors for predicting treatment response.
  • Utilizing viral kinetics to guide the duration of HCV therapy.
  • Evaluating higher-dose ribavirin for genotype 1 infections and retreatment strategies.

Main Results:

Related Experiment Videos

  • Pretreatment factors can significantly predict treatment response in HCV infection.
  • Viral kinetics offer a dynamic approach to personalize treatment length.
  • Higher ribavirin doses and retreatment protocols show promise for non-responders.

Conclusions:

  • Optimizing HCV treatment involves personalized strategies based on predictive factors and viral kinetics.
  • Addressing non-responders and relapsers with tailored retreatment is crucial.
  • Improving patient adherence is essential for successful HCV eradication.